Published in Arch Gen Psychiatry on October 01, 1990
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child (2005) 1.17
Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother (2013) 1.08
Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol (2008) 1.07
Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J Clin Psychiatry (2001) 0.97
Factors affecting sleep quality of patients in intensive care unit. J Clin Sleep Med (2012) 0.89
Glucocorticoids: complications to anticipate and prevent. Neurohospitalist (2013) 0.77
Metyrapone in treatment-resistant depression. Ther Adv Psychopharmacol (2012) 0.77
Effects of adrenal cortex hormones on limbic structures: some experimental and clinical correlations related to depression. J Psychiatry Neurosci (1993) 0.77
Stable Bipolar Patient Switched to Mania following Clinical Doses of Prednisone. Case Rep Psychiatry (2011) 0.75
Emotional lability secondary to the application of a very potent topical corticosteroid. Indian J Psychiatry (2009) 0.75
A comparison of clinician-rated neuropsychological and self-rated cognitive assessments in patients with asthma and rheumatologic disorders. Allergy Asthma Proc (2013) 0.75
Behavioural abnormalities in children with new-onset nephrotic syndrome receiving corticosteroid therapy: results of a prospective longitudinal study. Pediatr Nephrol (2015) 0.75
Inhaled steroid-induced mania in an adolescent girl: a case report. Prim Care Companion CNS Disord (2011) 0.75
Successful treatment of steroid-induced panic disorder with fluvoxamine. J Psychiatry Neurosci (1997) 0.75
Efficacy of tocilizumab for psychiatric symptoms associated with relapsing polychondritis: the first case report and review of the literature. Rheumatol Int (2016) 0.75
National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry (1991) 3.53
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A (1997) 3.00
Cognitive effects of corticosteroids. Am J Psychiatry (1990) 2.85
Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. J Clin Endocrinol Metab (1994) 2.71
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry (2000) 2.66
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993. Psychiatr Serv (2000) 2.43
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry (2000) 2.34
Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology (1997) 2.20
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19
The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry (1987) 2.19
Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry (2012) 2.07
Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet (2000) 2.05
Lethal catatonia. Am J Psychiatry (1986) 2.03
Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet (1997) 2.02
Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum (1994) 1.97
A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci U S A (1999) 1.96
Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry (1991) 1.94
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry (2000) 1.93
Cognitive substrates of thought disorder, I: the semantic system. Am J Psychiatry (1998) 1.90
NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 1.88
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol (2001) 1.86
Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol Psychiatry (2012) 1.84
The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later. Am J Psychiatry (1987) 1.80
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry (1999) 1.79
Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry (1993) 1.78
The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry (1993) 1.75
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J (2004) 1.74
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry (2002) 1.73
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry (1997) 1.64
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry (1999) 1.63
Close linkage of c-Harvey-ras-1 and the insulin gene to affective disorder is ruled out in three North American pedigrees. Nature (1987) 1.61
Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry (1993) 1.55
Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab (1997) 1.55
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry (2000) 1.54
Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis (1994) 1.54
Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. Arch Gen Psychiatry (1988) 1.53
Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice. J Neurosci (1999) 1.52
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry (1998) 1.51
Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatry (1993) 1.47
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res (2003) 1.47
Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med (1986) 1.45
Association between variation in the human KCNJ10 potassium ion channel gene and seizure susceptibility. Epilepsy Res (2004) 1.42
Prolonged duration of operation: an indicator of complicated surgery or of surgical (mis)management? Infection (2011) 1.42
Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res (2004) 1.42
Proteins released from liver after ischaemia induced an elevation of heart resistance against ischaemia-reperfusion injury: 1. Beneficial effect of protein fraction isolated from perfusate after ischaemia and reperfusion of liver. Gen Physiol Biophys (2003) 1.41
A quantitative analysis of smooth pursuit eye tracking in monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry (1997) 1.41
Suicidal behavior in chronic schizophrenic patients: a follow-up study. Can J Psychiatry (1986) 1.39
Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry (1998) 1.38
Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) (2006) 1.37
Effort and cognition in depression. Arch Gen Psychiatry (1982) 1.37
A search for susceptibility loci for anorexia nervosa: methods and sample description. Biol Psychiatry (2000) 1.36
Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA (1993) 1.34
Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry (1995) 1.31
Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) (1999) 1.30
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res (2003) 1.29
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther (2000) 1.29
Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab (1997) 1.28
Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry (1984) 1.28
Maternal inheritance and chromosome 18 allele sharing in unilineal bipolar illness pedigrees. Am J Med Genet (1996) 1.28
Reliability and acceptability of psychiatric diagnosis via telecommunication and audiovisual technology. Psychiatr Serv (1998) 1.27
Perfectionism in anorexia nervosa: variation by clinical subtype, obsessionality, and pathological eating behavior. Am J Psychiatry (2000) 1.27
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry (2001) 1.25
Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry (1993) 1.25
High plasma norepinephrine levels in patients with major affective disorder. Am J Psychiatry (1982) 1.21
Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med (1999) 1.21
Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch Gen Psychiatry (1994) 1.20
Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med (2000) 1.20
Borna disease virus and schizophrenia. Psychiatry Res (1995) 1.19
SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci (2001) 1.17
Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. Am J Hum Genet (2002) 1.17
Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res (1993) 1.17
Dopamine D2 receptor density and personal detachment in healthy subjects. Am J Psychiatry (1998) 1.16
Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol (1998) 1.16
Mapping murine loci for seizure response to kainic acid. Mamm Genome (1997) 1.15
The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology (2000) 1.14
Alterations in immunocompetence during stress, bereavement, and depression: focus on neuroendocrine regulation. Am J Psychiatry (1987) 1.14
The role of social relationships in the recovery from psychotic disorders. Am J Psychiatry (1984) 1.14
Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry (1990) 1.13
Characterization of schizophrenic patients who commit suicide. Am J Psychiatry (1984) 1.12
No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA (1994) 1.12
Temperament and character in women with anorexia nervosa. J Nerv Ment Dis (2000) 1.11
Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications. J Clin Endocrinol Metab (1991) 1.11
Differential effect of clozapine on weight: a controlled study. Am J Psychiatry (1996) 1.10
Self-control in psychotic disorders. Arch Gen Psychiatry (1983) 1.10
Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Ann Neurol (1989) 1.10
Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry (1997) 1.10
Alternative transcripts and evidence of imprinting of GNAL on 18p11.2. Mol Psychiatry (2005) 1.09
Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry (1988) 1.08